Literature DB >> 32200188

Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported.

Lucia Masarova1, Ruben Anthony Mesa2, Juan C Hernández-Boluda3, Jason A Taylor4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32200188      PMCID： PMC8895347          DOI： 10.1016/j.leukres.2020.106338

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  5 in total

1.  Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia.

Authors:  Juan-Carlos Hernández-Boluda; Juan-Gonzalo Correa; Alberto Alvarez-Larrán; Francisca Ferrer-Marín; José-María Raya; Joaquín Martínez-López; Patricia Velez; Manuel Pérez-Encinas; Natalia Estrada; Valentín García-Gutiérrez; María-Laura Fox; Elisa Luño; Ana Kerguelen; Beatriz Cuevas; María-Antonia Durán; María-José Ramírez; Maite Gómez-Casares; María-Isabel Mata-Vázquez; Anabel Regadera; Arturo Pereira; Francisco Cervantes
Journal:  Br J Haematol       Date:  2017-04-17       Impact factor: 6.998

2.  Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.

Authors:  Lucia Masarova; Ahmad Alhuraiji; Prithviraj Bose; Naval Daver; Naveen Pemmaraju; Jorge Cortes; Sherry Pierce; Hagop Kantarjian; Srdan Verstovsek
Journal:  Eur J Haematol       Date:  2018-01-17       Impact factor: 2.997

3.  Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Authors:  Allison H Scotch; Heidi Kosiorek; Robyn Scherber; Amylou C Dueck; Stefanie Slot; Sonja Zweegman; Peter A W Te Boekhorst; Suzan Commandeur; Harry Schouten; Federico Sackmann; Ana Kerguelen Fuentes; Dolores Hernández-Maraver; Heike L Pahl; Martin Griesshammer; Frank Stegelmann; Konstanze Döhner; Thomas Lehmann; Karin Bonatz; Andreas Reiter; Francoise Boyer; Gabriel Etienne; Jean-Christophe Ianotto; Dana Ranta; Lydia Roy; Jean-Yves Cahn; Claire N Harrison; Deepti Radia; Pablo Muxi; Norman Maldonado; Carlos Besses; Francisco Cervantes; Peter L Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Chiara Paoli; Francesco Passamonti; Bjorn Andreasson; Maria L Ferrari; Alessandro Rambaldi; Jan Samuelsson; Gunnar Birgegard; Zhijian Xiao; Zefeng Xu; Yue Zhang; Xiujuan Sun; Junqing Xu; Jean-Jacques Kiladjian; Peihong Zhang; Robert Peter Gale; Ruben A Mesa; Holly L Geyer
Journal:  Leuk Res       Date:  2017-10-14       Impact factor: 3.156

4.  Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Authors:  Constantine S Tam; Hagop Kantarjian; Jorge Cortes; Alice Lynn; Sherry Pierce; Lingsha Zhou; Michael J Keating; Deborah A Thomas; Srdan Verstovsek
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

5.  Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.

Authors:  Srdan Verstovsek; Jason Gotlib; Ruben A Mesa; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Francisco Cervantes; Claire N Harrison; Ronald Paquette; William Sun; Ahmad Naim; Peter Langmuir; Tuochuan Dong; Prashanth Gopalakrishna; Vikas Gupta
Journal:  J Hematol Oncol       Date:  2017-09-29       Impact factor: 17.388
  5 in total
  1 in total

1.  Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.

Authors:  Srdan Verstovsek; Ruben Mesa; Moshe Talpaz; Jean-Jacques Kiladjian; Claire N Harrison; Stephen T Oh; Alessandro M Vannucchi; Raajit Rampal; Bart L Scott; Sarah A Buckley; Adam R Craig; Karisse Roman-Torres; John O Mascarenhas
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.